L
ow-density lipoprotein-cholesterol (LDL-C) is a principal factor used by clinicians to make data-driven and guideline-recommended decisions regarding lipid-lowering therapy. [1] [2] [3] [4] [5] [6] It appears that patient groups most likely to benefit from lipid-lowering therapy are those identified based on a combination of risk and lipid levels. 7 Selected worldwide dyslipidemia guidelines and expert recommendations from the US National Lipid Association, Canadian Cardiovascular Society, European Society of Cardiology/European Atherosclerosis Society, and International Atherosclerosis Society recommend LDL-C targets of <70 and <100 mg/dL, respectively, for patients at very high-and high-risk for cardiovascular disease. 2, [4] [5] [6] Despite LDL-C target attainment, treatment may remain inadequate for several reasons. First, LDL-C may be underestimated by the classic Friedewald equation. 8 We previously demonstrated that individuals commonly have Friedewald-estimated LDL-C <70 mg/dL yet have a concentration ≥70 mg/dL when using a more accurate novel LDL-C estimate. 9 Second, the cholesterol concentration in remaining atherogenic lipoproteins, in particular very low-density lipoprotein-cholesterol (VLDL-C), may remain elevated. Non-high-density lipoprotein-cholesterol (non-HDL-C) incorporates VLDL-C and represents the total cholesterol concentration in all atherogenic particles. [10] [11] [12] [13] Third, even with controlled cholesterol measures (LDL-C and non-HDL-C), atherogenic lipoprotein load may remain elevated because of excess small, dense particles in hypertriglyceridemic states such as diabetes mellitus and obesity. 14, 15 Thus, a discordantly high-particle concentration state may exist and be detectable by apoB.
To address therapeutic adequacy, certain worldwide guidelines have designated secondary targets for non-HDL-C (<100 and <130 mg/dL) and apoB (<80 and <90 or <100 mg/dL) when the LDL-C target is achieved in very high-and high-risk patients, respectively. 2, 4, 5 Yet it remains unclear to what extent incorporating these secondary non-HDL-C and apoB targets into clinical practice could change management. Their ability to change management might be diminished after improved LDL-C accuracy because individuals reclassified to a higher LDL-C category using a more accurate novel LDL-C estimate also have higher non-HDL-C and apoB levels. 16 Therefore, the main scope of our study was to model operationalization of selected worldwide guidelines to assess for the first time how frequently using guidelinerecommended secondary non-HDL-C and apoB targets might lead to intensified lipid treatment beyond LDL-C, in particular after more accurate and modern LDL-C estimation. We assessed guideline cut points in all individuals meeting primary LDL-C cut points as well as in those with high-risk clinical features, including coronary artery disease, diabetes mellitus, and metabolic syndrome (akin to the types of patients for whom these targets are meant). We conducted cross-sectional analyses in the National Health and Nutrition Examination Survey (NHANES) and the Very Large Database of Lipids (VLDL), representing a general US sample complemented by a large clinical laboratory cohort.
METHODS
The data, analytic methods, and study materials are available to other researchers for purposes of reproducing the results. Study materials are securely housed at Johns Hopkins University and may be made available through remote access after completion of a data use agreement. Interested investigators may visit the VLDL clinicaltrials.gov site and contact the VLDL study Publications and Presentations Committee.
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NHANES and VLDL Study Populations
We included fasting NHANES participants from the 2011 to 2012 cycle and fasting patients from the second harvest of the VLDL study for primary analysis. NHANES is a nationally
Clinical Perspective
What Is New?
• Utility of current non-high-density lipoprotein-cholesterol targets is contingent on the accuracy of the LDL-C estimation.
• When using a novel, more accurate estimation method to assess low-density lipoprotein-cholesterol, non-high-density lipoprotein-cholesterol is infrequently above current guideline-suggested targets after the low-density lipoprotein-cholesterol (LDL-C) target is met.
• Current guideline-suggested apolipoprotein B targets also provide modest utility after cholesterol targets are met.
• These findings are robust to high-risk clinical features, sex, fasting status, and presence of lipid-lowering therapies.
What Are the Clinical Implications?
• In making evidence-based decisions about lipid-lowering therapy for the prevention of cardiovascular disease in high-risk individuals, a first step in assessing adequacy of therapy is ensuring the highest possible accuracy of the primary treatment target, LDL-C.
• Because clinical practice is focused on LDL-C, clinicians will be best supported in decision making if clinical laboratories update LDL-C estimation to the novel, more accurate method.
• Because current guideline-suggested non-highdensity lipoprotein-cholesterol and apolipoprotein B targets appear to have only modest potential to change management after more accurate LDL-C estimation, this may simplify current clinical practice and stimulate further work toward more actionable secondary lipid targets. The VLDL study consists of deidentified data from US patients referred for clinical lipid testing from predominantly outpatient primary care clinics. The processes of sample acquisition, data harvesting, and quality checks was described previously. 19 A total of 126 092 fasting adult patients from the second harvest of the VLDL study with complete lipid values and TG levels <400 mg/dL were included for primary analysis; 92 063 nonfasting patients with TG values <400 mg/dL and 2392 fasting patients from the VLDL study with TG values ≥400 mg/dL were included for secondary analyses. If a patient had >1 lipid sample available, then the first sample was used. The presence of lipid-lowering therapies and specific percentage of patients from primary care clinics were not known in VLDL study patients.
The study protocol for NHANES was approved by the Institutional Review Board of the National Center of Health Statistics, and all NHANES participants provided written informed consent. The VLDL study was declared exempt by the Johns Hopkins Institutional Review Board for informed consent as deidentified data were used. The Figure details the participant selection process for both cohorts. All authors attest to full data access and take responsibility for data integrity and analysis.
Lipid Measurements
In NHANES, total cholesterol, HDL-C, and TG were measured photometrically. 20 ApoB was measured using immunochemical reactions and light spectroscopy. 21 Within the VLDL cohort, vertical auto profile (VAP), a rapid ultracentrifugation technique that separates lipoproteins in <1 hour, was used to measure the cholesterol content in lipoprotein fractions. 19 TGs
were measured with the Abbott ARCHITECT C-8000 system, and apoB was measured with an Abbott ARCHITECT analyzer and reagent in accordance with World Health Organization standards. Quality assessments with the VAP and Abbott ARCHITECT system have been described in full previously.
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Statistical Analysis
LDL-C was calculated via the Friedewald equation as total cholesterol minus HDL-C minus TG/5 in mg/dL. 22 The novel estimation of LDL-C was calculated as total cholesterol minus HDL-C minus TG/adjustable factor in mg/dL, whereby 1 of 180 patient-specific ratios for VLDL-C estimation were set by non-HDL-C and TG categories as we have reported previously (Table I in the online-only Data Supplement). 9 As an example, if a patient's lipid panel is: total cholesterol, 160 mg/dL; HDL-C, 40 mg/dL; and TG, 250 mg/dL, then the patient's specific TG:VLDL-C ratio is 7.6 based on a non-HDL-C value of 120 mg/dL and a TG value of 250 mg/dL. Therefore, calculation of novel LDL-C is 160 mg/dL minus 40 mg/dL minus 250/7.6, which equals 87 mg/dL.
In both NHANES and VLDL cohorts, population-percentile-equivalent apoB values corresponding to LDL-C values of 70 mg/dL (very high risk) and 100 mg/dL (high risk) were determined using Friedewald and novel-derived LDL-C. As 1 example in NHANES individuals, a population-percentile apoB value of 59 mg/dL corresponded to a Friedewald LDL-C value of 70 mg/dL. This means that in NHANES participants, the same number of individuals have LDL-C values <70 mg/dL as have apoB values <59 mg/dL.
The percentages of individuals meeting LDL-C but not secondary non-HDL-C or apoB targets in both cohorts were calculated using the very high-and high-risk targets in the guidelines. For purposes of this analysis, the very-high risk secondary targets were <100 mg/dL and <80 mg/dL, respectively, for non-HDL-C and apoB. Targets of <130 and <100 mg/dL were chosen, respectively, as the high-risk secondary targets for non-HDL-C and apoB as per European Society of Cardiology/European Atherosclerosis Society recommendations. 4 The percentages of individuals who did not meet apoB targets after meeting dual LDL-C and ORIGINAL RESEARCH ARTICLE non-HDL-C targets were assessed and compared using the guideline apoB cut points versus population-percentilederived apoB cut points. For primary analysis, we assessed all fasting individuals with TG values <400 mg/dL in both study populations. In secondary NHANES analysis, we stratified our results by the presence of lipid-lowering therapy and high-risk clinical characteristics, including coronary artery disease, prediabetes, diabetes mellitus, and metabolic syndrome. For secondary analysis in the VLDL study, we conducted analyses in nonfasting samples and by VAP-measured LDL-C. We additionally investigated discordance in patients with TG ≥400 mg/dL.
In all NHANES analyses, we used sampling weights to account for the complex sampling design to obtain nationally representative results. Statistical analyses were conducted with Stata, version 14.2 (StataCorp).
RESULTS
Study Populations
Demographics and median cholesterol values for NHANES and VLDL participants are provided in Table 1 . The median age of the 2518 NHANES participants was 46 years (interquartile range, 32-60), with 48% men. This was in comparison with the 126 092 VLDL patients who had a median age of 58 years (interquartile range, 46-68), with 44% men. Median lipid values were similar between the 2 study cohorts.
Participants in NHANES were commonly overweight or obese, with ≈10% diagnosed with diabetes mellitus and ≈30% with hypertension. Nearly 1 out of every 3 participants was on lipid-lowering therapies. Table II in 
Population-Equivalent ApoB Cut Points
An apoB value of ≈60 mg/dL, with slight variations (ie, 57-63 mg/dL) depending on LDL-C estimation method and study cohort, corresponded to a population-percentile-equivalent LDL-C value of 70 mg/dL (ie, ≈7th-9th percentile) ( Table 2 ). In comparison, an apoB value of ≈80 mg/dL (range, 77-81 mg/dL) corresponded to a population-percentile-equivalent LDL-C value of 100 mg/dL (ie, ≈31st-36th percentile).
Lipid Targets
In fasting individuals, ≈7% to 9% had LDL-C values <70 mg/dL and 31% to 36% had LDL-C values <100 mg/dL (Table 3) . Of those with LDL-C <70 mg/dL, only 1% to 2% had non-HDL-C values ≥100 mg/dL when LDL-C was calculated using the novel equation compared with 14% to 15% when the Friedewald equation was used. Only a maximum of 8% of individuals had apoB values above the guideline target of <80 mg/dL, compared with 32% to 42% of individuals who had apoB values above the population-equivalent cut point of ≈60 mg/dL (Table 3) .
Among fasting individuals with LDL-C <100 mg/dL, only ≈2% of individuals had non-HDL-C values ≥130 mg/dL when LDL-C was calculated using the novel equation compared with 8% to 10% when calculated using the Friedewald equation. Furthermore, among individuals with LDL-C <100 mg/dL, 18% to 24% had apoB values above the population-percentile-equivalent apoB cut point of ≈80 mg/dL compared with a maximum of 3% for the guideline target of <100 mg/ dL (Table 3 ). These results were upheld when stratifying analysis by sex (Tables III and IV in the online-only Data Supplement).
In NHANES individuals with coronary artery disease and other high-risk clinical characteristics, findings remained robust (Table 4 ). In these high-risk groups, a maximum of ≈3% of individuals with novel LDL-C <70 mg/dL versus 38% with Friedewald LDL-C had non-HDL-C values ≥100 mg/dL. Similar trends were found in VLDL study individuals with VLDL when assessing the impact of nonfasting status and VAP-measured LDL-C (Table 5) . Notably, only 3% to 5% of nonfasting individuals with LDL-C <70 mg/dL had non-HDL-C values ≥100 mg/dL, respectively, after LDL-C was estimated with the novel method or measured via VAP. In comparison, nonfasting status had a greater impact on reclassification when LDL-C was estimated using the Friedewald equation: 21% of individuals with LDL-C <70 mg/dL had non-HDL-C values ≥100 mg/dL. Nonfasting apoB trends were similar to fasting apoB trends for each method of LDL-C.
When stratifying NHANES individuals by the presence of lipid-lowering therapies, a similar trend of only ≈1% of individuals on lipid-lowering agents with either novel-estimated LDL-C <70 mg/dL or <100 mg/dL had non-HDL-C values ≥100 and 130 mg/dL, respectively (Table V in the online-only Data Supplement). This was in comparison to 17% and 9% of individuals, respectively, when using Friedewald-estimated LDL-C. Nearly 12% of individuals on lipid-lowering therapies with Friedewald LDL-C <70 mg/dL had apoB values ≥80 mg/dL compared with ≈1% of individuals with novel LDL-C <70 mg/dL.
ApoB Utility After Dual Cholesterol Target Attainment
In all individuals meeting dual LDL-C (<70 mg/dL) and non-HDL-C (<100 mg/dL) targets, ≈0% to 1% had apoB values ≥80 mg/dL regardless of study cohort or LDL-C method used (Table 3 ). In comparison, 31% to 34% of all individuals and ≈40% to 50% of those with high-risk clinical characteristics had apoB values above 
ORIGINAL RESEARCH ARTICLE
population-equivalent targets of ≈<60 mg/dL after meeting the cholesterol targets (Tables 3 and 4) . In all individuals meeting dual LDL-C (<100 mg/dL) and non-HDL-C (<130 mg/dL) targets, a maximum of only 0.4% had apoB values ≥100 mg/dL (Table 3) . However, this percentage increased to 15% to 18% of all individuals and 20% to 44% of individuals with high-risk clinical characteristics when using a population-percentileequivalent apoB cut point of ≈80 mg/dL (Tables 3 and  4) . These trends were upheld regardless of sex (Tables  3 and 4 in the online-only Data Supplement), fasting status (Table 5) , and concomitant use of lipid-lowering therapy (Table V in 
Hypertriglyceridemia
Secondary analysis in 2393 patients from the VLDL study with TG values ≥400 mg/dL (representing 1.9% of the total study sample) demonstrated high levels of discordance at the guideline-recommended cut points (Table VI in the online-only Data Supplement). For example, >91% and 70% of patients, respectively, had non-HDL-C and apoB values above the very high-risk targets of <100 and <80 mg/dL after meeting the LDL-C target of <70 mg/dL. A higher percentage of patients (>95%) had apoB values at or above the very high-risk population-percentile target of <60 mg/dL. Discor- ApoB indicates apolipoprotein B; BMI, body mass index; HDL-C, high-density lipoprotein-cholesterol; IQR, interquartile range; LDL-C F , Friedewald-derived low-density lipoprotein-cholesterol; LDL-C N , novel method-derived low-density lipoprotein-cholesterol; NHANES, National Health and Nutrition Examination Survey; TG, triglyceride; VLDL-C, very low-density lipoprotein-cholesterol; VLDL-C F , Friedewald-derived very low-density lipoprotein-cholesterol; and VLDL-C N , novel method-derived very low-density lipoprotein-cholesterol.
*With survey statistics used in NHANES, participant n may not directly correspond to participant %.
†VLDL-C calculated via the novel method of TG/adjustable factor. 
DISCUSSION
In individuals with low LDL-C from both a general population sample and a large clinical sample, and in those with coronary artery disease and other high-risk clinical features, we found for the first time that only a small percentage of individuals have non-HDL-C values above guideline-recommended targets after using a novel algorithm that improves the accuracy of estimated LDL-C. Furthermore, current guideline apoB targets may provide minimal incremental utility in assessing treatment adequacy after meeting cholesterol targets.
Non-HDL-C Target Utility
LDL-C lowering remains the standard of care for primary and secondary prevention of cardiovascular disease, such as in patients with diabetes mellitus and coronary artery disease as studied here. In this setting, second- ApoB indicates apolipoprotein B; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; NHANES, National Health and Nutrition Examination Survey; PPV, population-percentile value, which depends on study population and LDL-C estimation; and VLDL, very large database of lipids.
*With survey statistics used in NHANES, participant n may not directly correspond to participant %; all NHANES individuals were fasting. 
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ary targets are recommended to address adequacy of therapeutic lipid intervention (ie, is there an opportunity to add additional proven therapy?) as highlighted by several international guidelines. The National Lipid Association and the International Atherosclerosis Society both recommend apoB as an optional secondary target after consideration of primary LDL-C and non-HDL-C. 2, 6 The 2016 Canadian Cardiovascular Society lipid guidelines mirror the European Society of Cardiology/ European Atherosclerosis Society guidelines in favoring LDL-C as a primary target and non-HDL-C and apoB as LDL-C <70 and non-HDL-C <100 mg/dL ApoB indicates apolipoprotein B; HDL-C, high-density lipoproteincholesterol; LDL-C: low-density lipoprotein-cholesterol; NHANES, National Health and Nutrition Examination Survey; PPV: population-percentile value, which depends on study population and LDL-C estimation; and TG: triglyceride.
*With survey statistics used in NHANES, participant n may not directly correspond to participant %; all NHANES individuals were fasting. ORIGINAL RESEARCH ARTICLE secondary, although the former only identifies patients at increased cardiovascular risk without subcategorizing into very high-and high-risk groups. 4, 5 In contrast, the American College of Cardiology/American Heart Association view non-HDL-C and apoB as key knowledge gaps that warrant further study. Non-HDL-C has been proposed as a surrogate marker of apoB and has been attractive for several reasons, including obviating the need for an additional test separate from standard lipid panels. The use of non-HDL-C depends on simple calculation with well agreed-on cut points (ie, 30 mg/dL greater than LDL-C) to guide therapy. [1] [2] [3] [4] [5] [6] Non-HDL-C incorporates cholesterol content in all atherogenic particles and is largely unaffected by fasting status. In our study, among those with high-risk features such as diabetes mellitus, metabolic syndrome, and coronary artery disease, a maximum of 38% of individuals with LDL-C <70 mg/dL and 33% of individuals with LDL-C <100 mg/dL had non-HDL-C values above guideline targets after meeting primary Friedewald-derived LDL-C targets.
Yet after incorporating a more accurate LDL-C estimation algorithm, current secondary non-HDL-C targets show modest utility. Accordingly, the utility of secondary non-HDL-C targets is contingent on calculating an accurate estimate of LDL-C. As we have previously shown, the Friedewald method underestimates LDL-C in the very group of individuals (ie, those with low LDL-C or high TG at high risk) where secondary targets are promoted by international guidelines. 8, 9 The Friedewald equation is also affected by fasting status, where fluctuations in the TG:VLDL-C ratio may cause imprecise estimation of LDL-C. Improving the fidelity of LDL-C with the novel method, where accuracy is maintained regardless of fasting status by using TG and non-HDL-C to derive patient-specific TG:VLDL-C ratios, could mitigate these issues and therefore streamline how clinicians monitor on-treatment response. 23 Non-HDL-C is inherently easier to calculate compared with Friedewald or novel methods given subtraction of only 1 component (HDL-C) from total cholesterol, rather than subtraction of 2 terms (HDL-C and estimated VLDL-C). From a laboratory reporting standpoint, however, novel LDL-C reporting may be automated and is already performed at clinical laboratories across the United States, including Quest Diagnostics. The novel method may also be freely calculated from a smartphone application (LDL cholesterol calculator: https://www.hopkinsmedicine.org/apps/all-apps/ldlcholesterol-calculator).
We acknowledge that prior studies have suggested modestly lower cut points for non-HDL-C corresponding to equivalent LDL-C population-percentile values. 13 These lower targets may represent opportunities to better assess treatment response with non-HDL-C once LDL-C accuracy is improved with the novel equation.
ApoB Target Utility
Discordantly high apoB despite controlled LDL and non-HDL cholesterol may be seen in high-risk patients such as those with coronary artery disease and diabetes mellitus. ApoB reflects the particle rather than cholesterol concentration of all circulating atherogenic lipoproteins. Several randomized controlled trials involving PCSK9 inhibitors and ezetimibe additive therapies have achieved on treatment apoB values much lower than suggested in the guidelines. [24] [25] [26] [27] [28] [29] The lower apoB cut points suggested by equivalent LDL-C population percentiles from our study are similar to those safely achieved with novel lipid-lowering agents among at-risk individuals in randomized controlled trials. ApoB indicates apolipoprotein B; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; PPV, population-percentile value, which depends on study population and LDL-C estimation; VAP, vertical auto profile; and VLDL, very large database of lipids.
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However, we note that it remains unclear whether improvement in cardiovascular outcomes from recent trials are attributable to lower apoB values independent of lower LDL-C values. We further acknowledge that apoB is not widely used and may remain problematic with regard to standardization. 30 The potential for longterm safety issues should continue to be studied, and there are other tradeoffs including the added costs of an apoB and resulting medications and clinic visits that need to be weighed against the expected benefits to specific outcomes in high-risk patient groups. [31] [32] [33] [34] [35] [36] Furthermore, no trial has yet specifically tested whether addition of further therapy to lower apoB beyond LDL-C may lead to improved clinical outcomes. Given the high incidence of atherosclerotic cardiovascular disease present throughout broad ranges of LDL-C, non-HDL-C, and apoB values, specific targets may require further prospective study, both on and off therapy (given differences in lipid composition).
Discordance at TG≥400 mg/dL
Although prior studies have shown additive information about risk prediction or response to therapy from non-HDL-C and lipoprotein particle measures, our analysis indicates that using such measures may uncommonly alter clinical care in individuals with TG values <400 mg/dL after accuracy of the primary treatment target, LDL-C, is addressed. [37] [38] [39] [40] However, in a small proportion of individuals (≈2%) with TG values ≥400 mg/dL, discordance is especially common because of increased synthesis or impaired clearance of VLDL particles resulting in discordantly high non-HDL-C and apoB. Therefore, secondary targets are less likely to be met. Nevertheless, the clinical priority in this range is TG control (reducing chylomicrons) to prevent acute pancreatitis. In this context, statins or other LDL-lowering agents may not be the appropriate next step in the management of discordance.
Limitations
There are some limitations to our study. The VLDL dataset does not include information on patient medications or other clinical data. However, guideline-directed therapy revolves around both pre-and ontreatment lipid monitoring in a wide variety of patients. Furthermore, to address this issue, we conducted additional analyses in NHANES stratified by the use of lipid-lowering therapy with similar results. Additionally, only the first lipid panel for patients with multiple entries was used for analysis; intrapatient variation, which may affect lipid goals, was not analyzed. However, in clinical practice, decisions are often made on the basis of single measurements. Although LDL particle concentration as a secondary target may demonstrate similar discordance with cholesterol targets to apoB, it was not available for analysis in our study samples. 41 We also did not investigate the effect of race on discordance.
Conclusions
In conclusion, we have shown for the first time that secondary non-HDL-C targets in selected worldwide dyslipidemia guidelines diminish in utility after accurately calculating LDL-C using a validated, easily calculable novel method, and this finding was consistent in highrisk individuals for whom primary and secondary targets apply. Furthermore, current guideline-suggested apoB targets provide limited utility in identifying individuals with elevated atherogenic particle burden after meeting cholesterol targets. Our results call for attention to LDL-C accuracy to best support clinical decision making using this primary treatment target, and our results may also stimulate more work toward more actionable secondary lipid targets. 
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